Grufity logo
Grufity logo
GLYC

GLYC - GlycoMimetics Inc Stock Price, Fair Value and News

$17.98 
Market Closed as of 03 Jun 2026, 04:00 pm ET

35/100

GLYC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

GLYC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GLYC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GLYC Price Action

Last 7 days

-0.4%

Last 30 days

-1.4%

Last 90 days

70.8%

Trailing 12 Months

-3.1%

GLYC RSI Chart

GLYC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GLYC Valuation

Market Cap

495.7M

Price/Earnings (Trailing)

-5.33

Price/Sales (Trailing)

45.72

EV/EBITDA

-2.02

Price/Free Cashflow

-7.02

GLYC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GLYC Fundamentals

GLYC Revenue

Rev. Growth (Yr)

5.0K%

Rev. Growth (Qtr)

609.23%

GLYC Earnings

Earnings (TTM)

-93.0M

Earnings Growth (Yr)

-53.7%

Earnings Growth (Qtr)

0.07%

GLYC Profitability

EBT Margin

-1401.16%

Return on Equity

-50.57%

Return on Assets

-46.69%

Free Cashflow Yield

-14.24%

GLYC Investor Care

Shares Dilution (1Y)

4172.59%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20254.4M6.6M8.7M10.8M
2022-179.3K179.2K2.3M
20216.2M2.2M1.3M1.2M
202029.1M22.8M16.5M10.2M
2015-35.1M20.0M20.1M
2014-6.8M12.3M15.0M
201312.4M9.6M6.8M4.0M
2012---15.3M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About GlycoMimetics Inc

GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEglycomimetics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES38

GlycoMimetics Inc Frequently Asked Questions

GLYC is the stock ticker symbol of GlycoMimetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jun 03 2026, market cap of GlycoMimetics Inc is 495.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jun 03 2026, GLYC's PE ratio (Price to Earnings) is -5.33 and Price to Sales (PS) ratio is 45.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GLYC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, GlycoMimetics Inc has provided -0.308 (multiply by 100 for percentage) rate of return.